FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Former Reviewer McGarry Joins Greenleaf Health

[ Price : $8.95]

Former FDA reviewer Sarah McGarry joins consulting firm Greenleaf Health as senior vice president of drug and biological products.

Rexulti Ads False and Misleading: OPDP

[ Price : $8.95]

The CDER Office of Prescription Drug Promotion says two Otsuka Rexulti ads contain misleading presentations of the drugs efficacy....

14 Observations in Kilitch India FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with 14 observations from an inspection at the Kilitch Healthcare India sterile drug manufacturing f...

FDA Proposes to Withdraw Carbadox Approval

[ Price : $8.95]

Federal Register notice: FDA proposes to withdraw approval of Phibro Animal Healths NADAs for carbadox in medicated swine feed.

Improve Cell, Gene Manufacturing Guidance: ISCT

[ Price : $8.95]

The International Society for Cell & Gene Therapy suggests ways to improve an FDA draft guidance on manufacturing changes and comp...

FTC Challenges Patent Listings in Orange Book

[ Price : $8.95]

In a major move against questionable drug patents, the FTC challenges the legitimacy of more than 100 patents listed in FDAs Orang...

Law Blog Faults FDA on Remote Evaluations

[ Price : $8.95]

Two Hyman, Phelps & McNamara staff say FDA missed an opportunity to conduct many remote interactive evaluations of drug manufactur...

Neurotris Illegally Marketing Devices: FDA

[ Price : $8.95]

FDA warns Irvine, CA-based Neurotris about multiple violations in its illegal manufacturing and distribution of muscle stimulator ...

Real-Time Oncology Review Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for select NDAs and BLAs submitted for Real-Time Oncology Review.

Imbria Moving Heart Drug to Phase 3

[ Price : $8.95]

Imbria Pharmaceuticals plans a Phase 3 study of ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation inhibito...